United States

AFFO (TTM)

AFFO/share (TTM)

AFFO/share Guidance

AFFO (Quarter)

AFFO/share (Quarter)

Price per share at the end of the period divided by the last reported earnings

Price/AFFO

Size (ft²)

Occupancy

The Company is a fully integrated REIT primarily focused on the ownership, acquisition, development and management of
retail properties net leased to industry leading tenants.

Agree Realty

The main earnings metric reported by the REIT

If the REIT is managed by an internal (employees) or external (separate company) team

As a long-term debt issuer, ADC is classified as investment grade

Period: 2023 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 15/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2023 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 13/15,
Adjusted FFO/share Growth: 18/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 10/15,
Adjusted FFO/share Growth: 15/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2024 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q3

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2025 Q4

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2026 Q1

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

Period: 2026 Q2

Years since IPO: 15/15,
Adjusted FFO Growth: 15/15,
Adjusted FFO/share Growth: 20/20,
Dividend Growth: 20/20,
Payout Ratio: 15/15,
Debt: 15/15
            

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's Adjusted FFO

Adjusted FFO Growth

Assessment of recent increases in Adjusted FFO per share, indicating profitability

Adjusted FFO/share Growth

Analysis of the recent Dividend track record

Dividend Growth

Payout level to determine if the dividend is safe

Payout Ratio

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) an innovation-driven, global biopharma company, today announced that it has entered into a securities purchase agreem

Zai Lab Announces $250 Million Private Placement

Where you hold a dividend portfolio matters almost as much as what you hold, and for one mix of REITs and a BDC generating nearly $45,000 a year, the difference between account types could quietly reshape your retirement math.

An $800,000 Portfolio Pays Nearly $3,800 a Month. How Much Would Taxes Take?

TOKYO--(BUSINESS WIRE)--Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO.

Daiichi Sankyo Highlights Ongoing Progress Across Industry-Leading ADC Portfolio with New Research Updates at ESMO

MAINZ, Germany, October 22, 2026 – BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced a clinical trial collaboration and supply agreement with Gilead Sciences Inc. (“Gilead”) to evaluate pumitamig in combination with the TROP2-directed antibody-drug conjugate (“ADC”) sacituzumab govitecan (Trodelvy®) as first-line treatment for patients with locally advanced or metastatic PD-L1 low or negative triple-negative breast cancer (“TNBC”). Pumitamig is an investigational bispecific immunomodulator designed to cooperatively bind to PD-L1 and VEGF-A that is being jointly developed by BioNTech and Bristol Myers Squibb (“BMS”).

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead's TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

Agree Realty reduced 2026 investment volume guidance to $1.6 billion. The company's retail portfolio reached 99.8% occupancy in the third quarter.

Agree Realty: 3 Key Takeaways for Long-Term Investors

Agree Realty NYSE: ADC reported third-quarter 2026 core funds from operations and adjusted funds from operations of $1.15 per share, each up 4.9% from the prior-year quarter, while maintaining portfolio occupancy of 99.8%.

What Agree Realty (ADC) Said on Its Q3 Earnings Call

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced results for the quarter ended September 30, 2026. All per share amounts included herein are on a diluted per common share basis unless otherwise stated. Third Quarter 2026 Financial and Operating Highlights: Invested approximately $358 million in 94 retail net lease properties Commenced six development or Developer Funding Platform (“DFP”) projects for total committed capital of approximately.

Agree Realty Corporation Reports Third Quarter 2026 Results

Parking high-yield BDCs and REITs in a taxable account quietly hands the IRS a check every April, and most investors never calculate exactly how much they are giving away each year across their entire portfolio.

A $750,000 Dividend Portfolio Could Lose $13,920 a Year to Taxes. Here's the Roth Alternative

Net lease REITs let you collect rent checks without fixing a single leaky faucet, but not all three of these monthly payers carry the same risks, growth rates, or tenant quality under the hood.

3 Dividend Stocks That Let You Collect Rent Without Becoming a Landlord

Montreal, Quebec--(Newsfile Corp. - October 19, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® drug-delivery platform, is pleased to announce two significant achievements at World ADC San Diego 2026, held October 12-15: winning the conference's Best Poster Award for its Accum ® -ADC research and leading a main-stage discussion alongside internationally recognized experts in antibody-drug conjugates ("ADCs"). These achievements highlight the growing recognition of Defence's Accum® technology within the global ADC community.

Defence Therapeutics Wins Best Poster Award and Takes Center Stage at World ADC San Diego 2026, a Key Recognition in the Field Highlighting the Potential of Its Accum Platform

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast CancerPR NewswireSHANGHAI, O

ESMO 2026 Preview | Mabwell to Present Clinical Results for Nectin-4-Targeting ADC 9MW2821 in ADC-Pretreated Triple-Negative Breast Cancer

/C O R R E C T I O N - AbbVie/PR NewswireNORTH CHICAGO, Ill., Oct. 18, 2026In the news release, AbbVie to Present Data at the 2026 European Society for Medical

/C O R R E C T I O N - AbbVie/

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor PortfolioPR News

AbbVie to Present Data at the 2026 European Society for Medical Oncology (ESMO) Congress Highlighting Progress Across its Expanding Solid Tumor Portfolio

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) CongressPR NewswireINDIANAPOLIS, Oct. 18, 2026F

Lilly to showcase advances across its oncology pipeline at the 2026 European Society for Medical Oncology (ESMO) Congress

Monthly bills arrive on a schedule that quarterly dividends cannot match, but five stocks pay 12 times a year with yields climbing as high as 6.65%. Two of them carry risks that could quietly shrink your paycheck before you notice.

5 Monthly Dividend Stocks Retirees Should Consider This Month

CEO Abizer Gaslightwala discusses Akari's novel PH1 payload strategy and execution priorities supporting AKTX-101's advancement toward planned Phase 1 clinical development in mid-2027

Akari Therapeutics CEO Highlights Differentiated ADC Payload Strategy and Path Toward Clinical Development in New CEO Corner

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that its Board of Directors has authorized, and the Company has declared, a monthly cash dividend of $0.271 per common share, representing a 1.5% month-over-month increase. The monthly dividend reflects an annualized dividend amount of $3.252 per common share, representing a 3.4% increase over the annualized dividend amount of $3.144 per common share from the fourth quarter of 2025. The divid.

Agree Realty Declares Increased Monthly Common Dividend

Mr. Vat-Ho's appointment adds more than 20 years of oncology, biopharma and capital markets experience, including senior roles in transactions totaling more than $25 billion in aggregate value

Akari Therapeutics Appoints Accomplished Oncology and ADC Deal Executive Vatnak Vat-Ho as Chief Business Officer to Drive Strategic Growth and Partnering

Some REITs pay dividends quarterly, but these five send checks every single month, and their cash flow coverage tells a more interesting story than the yield numbers alone.

Investors Love 5 Dividend Stocks That Pay Dependable Monthly Dividends

VERAXA Biotech presents first in vivo proof-of-concept for BiTAC®-ADC: tumor-selective activation with potent anti-tumor efficacy and improved safety.

VERAXA Biotech Presents in vivo Proof-of-Concept Data for BiTAC®-ADC Technology at World ADC Congress

CoreCap Advisors LLC lessened its position in Agree Realty Corporation (NYSE: ADC) by 94.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,213 shares of the real estate investment trust's stock after selling 76,056 shares during the quarter. CoreCap Advisors LLC's

Agree Realty Corporation $ADC Shares Sold by CoreCap Advisors LLC

As AI workloads increase in volume and complexity, Texas Instruments is delivering the essential solutions needed to power, monitor and optimize AI data centers  News highlights: TI's ADC34DSO75 is the industry's highest performance 3 gigasamples per second ADC, enabling 24/7, low-power, event-based remote monitoring at nanosecond resolution – thousands of times faster than what current solutions offer. The LMI800PS is the industry's first 800V isolated hot-swap controller, replacing a complex discrete solution requiring five integrated circuits with a single high-density package that delivers in-rush current and power path protection.

TI unveils new ADC to enable nanosecond-level telemetry and minimize downtime in AI data centers

Six holdings, no yield traps, and a monthly income target that demands you bring serious capital to the table. The real question is whether each payout can actually hold up when occupancy slips, cash flow disappoints, or litigation lands.

Could You Live on $6,750 a Month in Dividends? What It Takes, Without a Single Yield Trap

Two 59-year-olds hold the exact same six income funds at the exact same weights, yet one pays a federal penalty on every withdrawal while the other pockets the full amount tax-efficiently. The funds are not the problem.

Same Age, Same Savings: Why One 59-Year-Old Collects $5,550 a Month for Life and the Other Doesn’t

A stock-only portfolio paying over $12,000 a month sounds like a retirement dream, but the income splits into layers with very different levels of reliability. Before you build it, you need to know which part of that yield is real and which part is just your own money coming back to you.

$12,300 a Month in Dividends and Not One Bond: Is This Portfolio Too Good to Be True?

More than half of Americans fear outliving their savings, and the usual advice to "just invest" ignores the mismatch between quarterly payouts and monthly bills.

How to Turn $100,000 Into Steady Monthly Income for Retirement

A $500,000 portfolio of high-yield REITs and BDCs can quietly hand five figures every year straight to the IRS, and the account type you choose determines whether that loss compounds against you for decades.

Why High-Yield REITs and BDCs Can Be Powerful Income Stocks Inside a Roth IRA

Some dividends are backed by nothing more than last quarter's earnings, but a handful of companies collect rent, regulated utility bills, and trash pickup fees under contracts that make next year's cash flow visible before the year even begins.

5 Monthly Dividend Stocks That Could Turn Your Portfolio Into a Second Paycheck

$86.6 Million Private Placement announced, with participation from new and existing investors, extending expected cash runway into 2029  HealthCare Royalty financing agreement amended, removing change-of-control payment  Senior secure loan refinanced, decreasing principal to $50M with bullet payment in August 2029 and no minimum liquidity LAUSANNE, Switzerland, Oct. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced a comprehensive strategic financial restructuring designed to strengthen its balance sheet, reduce leverage, and increase strategic optionality to maximize shareholder value while extending the expected cash runway into 2029. The strategic initiative includes securing new equity financing, restructuring the HealthCare Royalty (HCR) agreement, and reducing the outstanding loan principal.

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

Both Realty Income and Agree Realty pay monthly dividends, own net lease properties, and have pulled back sharply in recent weeks, but holding the wrong one through retirement could cost you decades of compounding growth.

Realty Income or Agree Realty: If I Could Only Collect One Monthly Dividend Until Retirement, It Would Be This One

Both NNN and Agree Realty cut identical deals with tenants, raised guidance the same summer, and dropped nearly the same amount in price last month, yet one of them suits a retiree's portfolio far better than the other.

Better Dividend Stock for 2026: NNN or ADC? One Clearly Wins on Yield and Growth

Monthly dividends sound like a paycheck replacement, but the schedule is the easy part. Three REITs with October checks on the calendar reveal just how different safety, growth, and risk can look behind identical payment frequencies.

3 Monthly Dividend Payers That Could Replace an October Paycheck

Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca's (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The e

AstraZeneca Completes $2 Billion Equity Investment in Summit Therapeutics

Patent discloses uses beyond ADCs, including autologous or allogeneic adoptive cellular immunotherapies like CAR-T,  Tregs or TIL cell therapies TAMPA, Fla., Oct. 5, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced that the United States Patent and Trademark Office has issued U.S. Patent No.

TuHURA Biosciences Receives Key U.S. Patent for its Groundbreaking Delta Opioid Receptor (DOR) Antibody Drug Conjugate (ADC) Technology

Phase 1/2 APOLLO global clinical trial to evaluate CR-002 in multiple solid tumor types, including non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC), on track to initiate in the fourth quarter of 2026

Crescent Biopharma Announces FDA Clearance of IND Application for CR-002, a PD-L1-targeted Topoisomerase Inhibitor ADC, for the Treatment of Solid Tumors

Three income buckets and eight holdings can close the gap between your current savings and a five-figure monthly paycheck, but the math behind each yield level reveals a trade-off most investors never think to calculate.

How to Build $12,100 a Month in Dividend Income From Three Income Buckets

[url="]Genmab A/S[/url] (Nasdaq: GMAB) today announced results from Part C of the Phase 1/2 RAINFOLâ¢-01 trial evaluating rinatabart sesutecan (Rina-S), an inv

Genmab Announces Rinatabart Sesutecan (Rina-S®) Phase 2 RAINFOL™-01 Results Demonstrated Durable and Clinically Meaningful Responses in Patients with Platinum-Resistant Ovarian Cancer

Most retirees lean on Social Security as their primary income, but a dividend portfolio sized correctly could double that monthly check entirely. The catch is that choosing the wrong yield tier could cost you hundreds of thousands of dollars or quietly erode your principal over time.

How Much Do You Need Invested to Double the Average Social Security Check With Dividends?

Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE:

Summit Therapeutics Announces Clinical Trial Collaboration with AstraZeneca and Daiichi Sankyo to Evaluate Ivonescimab in Combination with TROP2-Directed ADC Datroway

The 10-year Treasury yield just hit a year-long high and dragged every one of these net lease REITs down with it, but falling share prices and failing dividends are not the same thing, and the difference matters more right now

Rates Are Hammering REITs. These 5 Dividends Are Built to Hold Up

Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing next-generation precision oncology therapeutics using its proprietary Accum® platform, is pleased to announce its participation in the 17th World ADC San Diego, taking place October 12-15, 2026, in San Diego, California. World ADC San Diego is a leading global forum dedicated to antibody-drug conjugates ("ADCs"), bringing together leaders from pharmaceutical and biotechnology companies, emerging innovators, academia and the clinical community to exchange scientific insights, foster collaboration and advance the development of next-generation ADCs.

Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates

ROYAL OAK, Mich.--(BUSINESS WIRE)--Agree Realty Corporation (NYSE: ADC) (the “Company”) today announced that it will release its third quarter 2026 operating results after the market closes on Tuesday, October 20, 2026. A conference call to discuss the Company's operating results is scheduled for Wednesday, October 21, 2026, at 9:00 AM ET. Interested parties and shareholders may access the call via teleconference or webcast: Teleconference: USA Toll Free (833) 461-5787 International (626) 884-3.

Agree Realty Announces Third Quarter 2026 Earnings Release Date and Conference Call Information

A 10-year Treasury sitting at a 52-week high just made dividend investing a lot harder, yet five monthly payers are still fighting for retirees' portfolios with yields, coverage ratios, and dividend growth records that demand a closer look.

5 Safest High-Yield Monthly Dividend Stocks Retirees Trust

At 64, with Medicare a year away and Social Security not yet kicking in, your portfolio may have to cover every single bill on its own. The yield you chase will determine whether you need twice as much saved as someone willing to take on more risk.

How Much Does a 64-Year-Old Need Invested to Collect $6,150 a Month?

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORT

Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026

Agree Realty Corporation (NYSE: ADC - Get Free Report) announced a monthly dividend on Thursday, September 10th. Investors of record on Wednesday, September 30th will be paid a dividend of $0.2670 per share by the real estate investment trust on Wednesday, October 14th. This represents a $3.20 dividend on an annualized basis and a yield of

Agree Realty Corporation (ADC) To Go Ex-Dividend on September 30th

Chasing the highest dividend yield is exactly how investors end up owning something that quietly eats their principal alive. A six-holding portfolio shows how a much lower yield can generate far more income a decade from now than a double-digit payout ever could.

How to Build $7,250 a Month in Dividend Income Without Owning a Single Yield Trap

Agree Realty Corporation (NYSE: ADC - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the sixteen brokerages that are currently covering the company, MarketBeat.com reports. Four analysts have rated the stock with a hold recommendation, eleven have assigned a buy recommendation and one has assigned a strong buy recommendation to the company.

Agree Realty Corporation (NYSE:ADC) Stock Rated “Moderate Buy” by Wall Street Brokerages

Boomer income investors want one thing above the rest: reliable checks that land every month. This September lineup spreads that mandate across four distinct income engines: net-lease retail, industrial warehouses, lower-middle-market private credit, and buyout-focused private credit.

5 Safe Monthly Pay Dividend Stocks Boomers Love in September

Building nearly $100,000 a year in dividend income without touching a single bond sounds like a tall order, but the real challenge is choosing which yield tier quietly destroys your wealth over time.

How to Build $8,150 a Month in Dividend Income Without Owning a Single Bond

TOKYO--(BUSINESS WIRE)--DAIICHI SANKYO HIGHLIGHTS ONGOING PROGRESS ACROSS INDUSTRY-LEADING ADC PORTFOLIO WITH NEW RESEARCH UPDATES AT ESMO.

DAIICHI SANKYO HIGHLIGHTS ONGOING PROGRESS ACROSS INDUSTRY-LEADING ADC PORTFOLIO WITH NEW RESEARCH UPDATES AT ESMO

MAINZ, GERMANY, OCTOBER 22, 2026  BIONTECH SE (NASDAQ: BNTX, BIONTECH) TODAY ANNOUNCED A CLINICAL TRIAL COLLABORATION AND SUPPLY AGREEMENT WITH GILEAD SCIENCES INC. (GILEAD) TO EVALUATE PUMITAMIG IN COMBINATION WITH THE TROP2-DIRECTED ANTIBODY-DRUG CONJUGATE (ADC) SACITUZUMAB GOVITECAN (TRODELVY) AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC PD-L1 LOW OR NEGATIVE TRIPLE-NEGATIVE BREAST CANCER (TNBC). PUMITAMIG IS AN INVESTIGATIONAL BISPECIFIC IMMUNOMODULATOR DESIGNED TO COOPERATIVELY BIND TO PD-L1 AND VEGF-A THAT IS BEING JOINTLY DEVELOPED BY BIONTECH AND BRISTOL MYERS SQUIBB (BMS).

BIONTECH ADVANCES PHASE 3 CLINICAL TRIAL OF PUMITAMIG IN COMBINATION WITH GILEAD'S TROP2-DIRECTED ADC SACITUZUMAB GOVITECAN IN TRIPLE-NEGATIVE BREAST CANCER

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2026. ALL PER SHARE AMOUNTS INCLUDED HEREIN ARE ON A DILUTED PER COMMON SHARE BASIS UNLESS OTHERWISE STATED. THIRD QUARTER 2026 FINANCIAL AND OPERATING HIGHLIGHTS: INVESTED APPROXIMATELY $358 MILLION IN 94 RETAIL NET LEASE PROPERTIES COMMENCED SIX DEVELOPMENT OR DEVELOPER FUNDING PLATFORM (DFP) PROJECTS FOR TOTAL COMMITTED CAPITAL OF APPROXIMATELY.

AGREE REALTY CORPORATION REPORTS THIRD QUARTER 2026 RESULTS

MONTREAL, QUEBEC--(NEWSFILE CORP. - OCTOBER 19, 2026) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("DEFENCE" OR THE "COMPANY"), A PUBLICLY TRADED BIOTECHNOLOGY COMPANY DEVELOPING NEXT-GENERATION PRECISION ONCOLOGY THERAPEUTICS USING ITS PROPRIETARY ACCUM DRUG-DELIVERY PLATFORM, IS PLEASED TO ANNOUNCE TWO SIGNIFICANT ACHIEVEMENTS AT WORLD ADC SAN DIEGO 2026, HELD OCTOBER 12-15:WINNING THE CONFERENCE'S BEST POSTER AWARD FOR ITS ACCUM  -ADC RESEARCH AND LEADING A MAIN-STAGE DISCUSSION ALONGSIDE INTERNATIONALLY RECOGNIZED EXPERTS IN ANTIBODY-DRUG CONJUGATES ("ADCS"). THESE ACHIEVEMENTS HIGHLIGHT THE GROWING RECOGNITION OF DEFENCE'S ACCUM TECHNOLOGY WITHIN THE GLOBAL ADC COMMUNITY.

DEFENCE THERAPEUTICS WINS BEST POSTER AWARD AND TAKES CENTER STAGE AT WORLD ADC SAN DIEGO 2026, A KEY RECOGNITION IN THE FIELD HIGHLIGHTING THE POTENTIAL OF ITS ACCUM PLATFORM

CEO ABIZER GASLIGHTWALA DISCUSSES AKARI'S NOVEL PH1 PAYLOAD STRATEGY AND EXECUTION PRIORITIES SUPPORTING AKTX-101'S ADVANCEMENT TOWARD PLANNED PHASE 1 CLINICAL DEVELOPMENT IN MID-2027

AKARI THERAPEUTICS CEO HIGHLIGHTS DIFFERENTIATED ADC PAYLOAD STRATEGY AND PATH TOWARD CLINICAL DEVELOPMENT IN NEW CEO CORNER

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.271 PER COMMON SHARE, REPRESENTING A 1.5% MONTH-OVER-MONTH INCREASE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.252 PER COMMON SHARE, REPRESENTING A 3.4% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.144 PER COMMON SHARE FROM THE FOURTH QUARTER OF 2025. THE DIVID.

AGREE REALTY DECLARES INCREASED MONTHLY COMMON DIVIDEND

MR. VAT-HO'S APPOINTMENT ADDS MORE THAN 20 YEARS OF ONCOLOGY, BIOPHARMA AND CAPITAL MARKETS EXPERIENCE, INCLUDING SENIOR ROLES IN TRANSACTIONS TOTALING MORE THAN $25 BILLION IN AGGREGATE VALUE

AKARI THERAPEUTICS APPOINTS ACCOMPLISHED ONCOLOGY AND ADC DEAL EXECUTIVE VATNAK VAT-HO AS CHIEF BUSINESS OFFICER TO DRIVE STRATEGIC GROWTH AND PARTNERING

VERAXA BIOTECH PRESENTS FIRST IN VIVO PROOF-OF-CONCEPT FOR BITAC-ADC: TUMOR-SELECTIVE ACTIVATION WITH POTENT ANTI-TUMOR EFFICACY AND IMPROVED SAFETY.

VERAXA BIOTECH PRESENTSIN VIVO PROOF-OF-CONCEPT DATA FOR BITAC-ADC TECHNOLOGY AT WORLD ADC CONGRESS

AS AI WORKLOADS INCREASE IN VOLUME AND COMPLEXITY, TEXAS INSTRUMENTS IS DELIVERING THE ESSENTIAL SOLUTIONS NEEDED TO POWER, MONITOR AND OPTIMIZE AI DATA CENTERS NEWS HIGHLIGHTS: TI'S ADC34DSO75 IS THE INDUSTRY'S HIGHEST PERFORMANCE 3 GIGASAMPLES PER SECOND ADC, ENABLING 24/7, LOW-POWER, EVENT-BASED REMOTE MONITORING AT NANOSECOND RESOLUTION  THOUSANDS OF TIMES FASTER THAN WHAT CURRENT SOLUTIONS OFFER. THE LMI800PS IS THE INDUSTRY'S FIRST 800V ISOLATED HOT-SWAP CONTROLLER, REPLACING A COMPLEX DISCRETE SOLUTION REQUIRING FIVE INTEGRATED CIRCUITS WITH A SINGLE HIGH-DENSITY PACKAGE THAT DELIVERS IN-RUSH CURRENT AND POWER PATH PROTECTION.

TI UNVEILS NEW ADC TO ENABLE NANOSECOND-LEVEL TELEMETRY AND MINIMIZE DOWNTIME IN AI DATA CENTERS

$86.6 MILLION PRIVATE PLACEMENT ANNOUNCED, WITH PARTICIPATION FROM NEW AND EXISTING INVESTORS, EXTENDING EXPECTED CASH RUNWAY INTO 2029 HEALTHCARE ROYALTY FINANCING AGREEMENT AMENDED, REMOVING CHANGE-OF-CONTROL PAYMENT SENIOR SECURE LOAN REFINANCED, DECREASING PRINCIPAL TO $50M WITH BULLET PAYMENT IN AUGUST 2029 AND NO MINIMUM LIQUIDITY LAUSANNE, SWITZERLAND, OCT. 8, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT), A COMMERCIAL-STAGE GLOBAL LEADER AND PIONEER IN THE FIELD OF ANTIBODY DRUG CONJUGATES (ADCS), TODAY ANNOUNCED A COMPREHENSIVE STRATEGIC FINANCIAL RESTRUCTURING DESIGNED TO STRENGTHEN ITS BALANCE SHEET, REDUCE LEVERAGE, AND INCREASE STRATEGIC OPTIONALITY TO MAXIMIZE SHAREHOLDER VALUE WHILE EXTENDING THE EXPECTED CASH RUNWAY INTO 2029. THE STRATEGIC INITIATIVE INCLUDES SECURING NEW EQUITY FINANCING, RESTRUCTURING THE HEALTHCARE ROYALTY (HCR) AGREEMENT, AND REDUCING THE OUTSTANDING LOAN PRINCIPAL.

ADC THERAPEUTICS ANNOUNCES COMPREHENSIVE STRATEGIC FINANCIAL RESTRUCTURING MARKING KEY CAPITAL STRUCTURE IMPROVEMENTS

PATENT DISCLOSES USES BEYOND ADCS, INCLUDING AUTOLOGOUS OR ALLOGENEIC ADOPTIVE CELLULAR IMMUNOTHERAPIES LIKE CAR-T, TREGS OR TIL CELL THERAPIES TAMPA, FLA., OCT. 5, 2026 /PRNEWSWIRE/ -- TUHURA BIOSCIENCES, INC. (NASDAQ:HURA) ("TUHURA" OR THE "COMPANY"), A PHASE 3 IMMUNO-ONCOLOGY COMPANY DEVELOPING NOVEL THERAPEUTICS TO OVERCOME RESISTANCE TO CANCER IMMUNOTHERAPY, TODAY ANNOUNCED THAT THE UNITED STATES PATENT AND TRADEMARK OFFICE HAS ISSUED U.S. PATENT NO.

TUHURA BIOSCIENCES RECEIVES KEY U.S. PATENT FOR ITS GROUNDBREAKING DELTA OPIOID RECEPTOR (DOR) ANTIBODY DRUG CONJUGATE (ADC) TECHNOLOGY

PHASE 1/2 APOLLO GLOBAL CLINICAL TRIAL TO EVALUATE CR-002 IN MULTIPLE SOLID TUMOR TYPES, INCLUDING NON-SMALL CELL LUNG CANCER (NSCLC) AND HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC), ON TRACK TO INITIATE IN THE FOURTH QUARTER OF 2026

CRESCENT BIOPHARMA ANNOUNCES FDA CLEARANCE OF IND APPLICATION FOR CR-002, A PD-L1-TARGETED TOPOISOMERASE INHIBITOR ADC, FOR THE TREATMENT OF SOLID TUMORS

MONTREAL, QUEBEC--(NEWSFILE CORP. - OCTOBER 1, 2026) - DEFENCE THERAPEUTICS INC. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("DEFENCE" OR THE "COMPANY"), A PUBLICLY TRADED BIOTECHNOLOGY COMPANY DEVELOPING NEXT-GENERATION PRECISION ONCOLOGY THERAPEUTICS USING ITS PROPRIETARY ACCUM PLATFORM, IS PLEASED TO ANNOUNCE ITS PARTICIPATION IN THE 17TH WORLD ADC SAN DIEGO, TAKING PLACE OCTOBER 12-15, 2026, IN SAN DIEGO, CALIFORNIA. WORLD ADC SAN DIEGO IS A LEADING GLOBAL FORUM DEDICATED TO ANTIBODY-DRUG CONJUGATES ("ADCS"), BRINGING TOGETHER LEADERS FROM PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, EMERGING INNOVATORS, ACADEMIA AND THE CLINICAL COMMUNITY TO EXCHANGE SCIENTIFIC INSIGHTS, FOSTER COLLABORATION AND ADVANCE THE DEVELOPMENT OF NEXT-GENERATION ADCS.

DEFENCE THERAPEUTICS TO TAKE THE STAGE AT WORLD ADC SAN DIEGO TO DISCUSS THE NEXT FRONTIER IN ANTIBODY-DRUG CONJUGATES

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT IT WILL RELEASE ITS THIRD QUARTER 2026 OPERATING RESULTS AFTER THE MARKET CLOSES ON TUESDAY, OCTOBER 20, 2026. A CONFERENCE CALL TO DISCUSS THE COMPANY'S OPERATING RESULTS IS SCHEDULED FOR WEDNESDAY, OCTOBER 21, 2026, AT 9:00 AM ET. INTERESTED PARTIES AND SHAREHOLDERS MAY ACCESS THE CALL VIA TELECONFERENCE OR WEBCAST: TELECONFERENCE: USA TOLL FREE (833) 461-5787 INTERNATIONAL (626) 884-3.

AGREE REALTY ANNOUNCES THIRD QUARTER 2026 EARNINGS RELEASE DATE AND CONFERENCE CALL INFORMATION

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS OPERATING PARTNERSHIP, AGREE LIMITED PARTNERSHIP (THE OPERATING PARTNERSHIP), PRICED A PUBLIC OFFERING OF $400 MILLION OF ITS 5.650% SENIOR UNSECURED NOTES DUE 2036 (THE NOTES). THE PUBLIC OFFERING PRICE FOR THE NOTES WAS 98.497% OF THE PRINCIPAL AMOUNT FOR AN EFFECTIVE YIELD TO MATURITY OF 5.849%. THE NOTES WILL BE SENIOR UNSECURED OBLIGATIONS OF THE OPERATING PARTNERSHIP, GUARA.

AGREE REALTY ANNOUNCES PRICING OF $400 MILLION OF 5.650% SENIOR UNSECURED NOTES DUE 2036

PTK7 EXPRESSION REMAINED STABLE FOLLOWING STANDARD-OF-CARE THERAPIES, SUPPORTING ITS RELEVANCE AS A TARGET IN SECOND- OR LATER-LINE EGFR NSCLC FINDINGS REINFORCE THE SCIENTIFIC RATIONALE FOR HWK-007, WHITEHAWK'S NEXT-GENERATION PTK7-DIRECTED ADC CURRENTLY IN PHASE 1 DEVELOPMENT MORRISTOWN, N.J., SEPT. 13, 2026 /PRNEWSWIRE/ -- WHITEHAWK THERAPEUTICS, INC.(NASDAQ: WHWK), A CLINICAL-STAGE ONCOLOGY THERAPEUTICS COMPANY APPLYING ADVANCED TECHNOLOGIES TO ESTABLISHED TUMOR BIOLOGY TO EFFICIENTLY DEVELOP IMPROVED ANTIBODY DRUG CONJUGATE (ADC)CANCER TREATMENTS, TODAY ANNOUNCED THE PRESENTATION OF TWO REAL-WORLD ANALYSES SUPPORTING PROTEIN TYROSINE KINASE 7 (PTK7) AS A DURABLE AND CLINICALLY RELEVANT ADC TARGET IN PATIENTS WITH PRETREATED, EGFR WILD-TYPE NON-SMALL CELL LUNG CANCER (NSCLC).

WHITEHAWK THERAPEUTICS PRESENTS REAL-WORLD ANALYSES SUPPORTING PTK7 AS A DURABLE ADC TARGET IN EGFR WILD-TYPE NON-SMALL CELL LUNG CANCER AT WCLC 2026

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE "COMPANY") TODAY ANNOUNCED THE RELEASE OF ITS 2025 SUSTAINABILITY REPORT. THE REPORT HIGHLIGHTS THE COMPANY'S ENVIRONMENTAL, SOCIAL AND GOVERNANCE ("ESG") INITIATIVES AND IS ALIGNED WITH THE ISSB IFRS S1 AND S2 DISCLOSURE STANDARDS. "I'M VERY PLEASED TO SHARE OUR SIXTH ANNUAL SUSTAINABILITY REPORT," SAID PETER COUGHENOUR, CHIEF FINANCIAL OFFICER. DURING 2025, WE DEEPENED OUR ENGAGEMENT WITH TENANTS ACROSS OUR PORTFOLIO.

AGREE REALTY PUBLISHES SIXTH ANNUAL SUSTAINABILITY REPORT

ROYAL OAK, MICH.--(BUSINESS WIRE)--AGREE REALTY CORPORATION (NYSE: ADC) (THE COMPANY) TODAY ANNOUNCED THAT ITS BOARD OF DIRECTORS HAS AUTHORIZED, AND THE COMPANY HAS DECLARED, A MONTHLY CASH DIVIDEND OF $0.267 PER COMMON SHARE. THE MONTHLY DIVIDEND REFLECTS AN ANNUALIZED DIVIDEND AMOUNT OF $3.204 PER COMMON SHARE, REPRESENTING A 4.3% INCREASE OVER THE ANNUALIZED DIVIDEND AMOUNT OF $3.072 PER COMMON SHARE FROM THE THIRD QUARTER OF 2025. THE DIVIDEND IS PAYABLE OCTOBER 14, 2026 TO STOCKHOLDERS O.

AGREE REALTY DECLARES MONTHLY COMMON AND PREFERRED DIVIDENDS

COMPANY INVITED TO PRESENT ALONGSIDE GLOBAL PHARMACEUTICAL, BIOTECHNOLOGY AND INDUSTRY LEADERS AT FIVE HIGH-PROFILE U.S. AND CHINA CONFERENCES IN SEPTEMBER

AKARI THERAPEUTICS SELECTED TO SHOWCASE NOVEL PH1 ADC PAYLOAD PLATFORM AT LEADING GLOBAL ONCOLOGY, ADC AND HEALTHCARE FORUMS

FIRST-IN-CLASS CEACAM5-TARGETING ADC ARMED WITH A PAN-RAS(ON) INHIBITOR  DESIGNED FOR TUMOR-SELECTIVE RAS PATHWAY INHIBITION FIRST PATIENT DOSED IN AUSTRALIA; GLOBAL PHASE I INITIATED U.S. FDA CLEARED IND WITH "STUDY-MAY-PROCEED" LETTER SINGAPORE AND NORTH BRUNSWICK, N.J., SEPT. 08, 2026 (GLOBE NEWSWIRE) -- ADLAI NORTYE GROUP LTD.

ADLAI NORTYE ANNOUNCES FIRST PATIENT DOSED IN AUSTRALIA AND U.S. FDA IND CLEARANCE FOR AN4035, A FIRST-IN-CLASS PAN-RAS(ON) INHIBITOR-BASED ADC

LAUSANNE, SWITZERLAND, SEPT. 3, 2026 /PRNEWSWIRE/ -- ADC THERAPEUTICS SA (NYSE: ADCT) TODAY ANNOUNCED THAT AMEET MALLIK, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT AT THE 2026 CANTOR GLOBAL HEALTHCARE CONFERENCE IN NEW YORK, NY, ON FRIDAY, SEPTEMBER 11, 2026, AT 9:10 A.M.

Agree Realty

ADC

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Dividends

Yield

Dividends

No items found.

Financial Reports

No items found.

Diversification by Property Type

Diversification by Tenant Industry

Diversification by Country

Historical Scores

Press Releases

Related News, Articles and Videos

You might also be interested in

ADC